


National Institute of Pharmaceutical Education and Research in Rae Bareli inks MoU with Boehringer Ingelheim India

21 February 2026 | News

Second batch of AMRUTVA unveiled to strengthen India's pharmaceutical sector



In a bid to promote pharmaceutical education and research in India, a Memorandum of Understanding (MoU) has been signed between the Rae Bareli-based National Institute of Pharmaceutical Education and Research (NIPER) and Boehringer Ingelheim India. The MoU was signed in the presence of Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers in New Delhi.

On this occasion, the second batch of AMRUTV (Alliance for Pharmaceutical Research, Innovation, Translational Research and Value Acceleration) was also launched to strengthen India's innovation ecosystem and enable conversion of research outcomes into viable pharmaceutical products and entrepreneurial ventures.

AMRUTV is being implemented by the Startup Incubation and Innovation Centre (SIIC), IIT Kanpur in collaboration with NIPER. The initiative is supported by Boehringer Ingelheim India Private Limited under Corporate Social Responsibility (CSR).

In his address, Manoj Joshi emphasised the role of collaborative partnerships between academia and industry in strengthening the process from research to market. He said that such initiatives are crucial for fostering domestic innovation capabilities, encouraging entrepreneurship, and ensuring wider access to affordable healthcare solutions.

Under the second group, five innovators have been selected for grant support to facilitate commercialization of their research. Three projects run by faculty members have been provided financial assistance of Rs 8 lakh each while two projects run by research scholars have been supported with a grant of Rs 6 lakh each.

The MoU signed between Boehringer Ingelheim India and NIPER Rae Bareilly also includes the Centre of Excellence for New Drug Delivery Systems (CoE-NDDS). It establishes a framework for strengthening academic and research collaborations in areas such as pharmaceutical technologies, innovative drug delivery systems, academic exchanges, and capacity-building programs.

As part of this collaboration, Boehringer Ingelheim will provide researchers and institutions with access to its opnMe® Open Science platform, enabling scientific exchange and accelerating innovation in healthcare.